This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mori, M. Articles by Inoue, H. Search for Related Content PubMed PubMed Citation Articles by Mori, M. Articles by Inoue, H.

Absence of Msh2 Protein Expression Is Associated with Alteration in the FHIT Locus and Fhit Protein Expression in Colorectal Carcinoma

Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, Japan

Frequent loss of Fhit expression has been reported in human gastrointestinal tract carcinomas; opinions remain divergent regarding Fhit expression in colorectal carcinoma (CRC) cases. Recent studies have suggested that Fhit inactivation can be a consequence of defects in mismatch repair proteins, particularly Msh2. Immunohistochemical analysis of Msh2 and Fhit protein expression in 62 CRC cases was performed. The same CRCs were examined for allelic loss at three loci within or near FHIT and for FHIT mRNA expression by reverse transcription-PCR amplification. Half of the 62 CRC cases were positive for Fhit protein. Fhit protein loss correlated significantly with the progression of carcinoma (P < 0.01) as well as lymph node metastasis (P < 0.05). Loss of Msh2 protein correlated significantly with loss of Fhit protein (P < 0.05) and FHIT locus alteration (P < 0.05). Loss of Fhit protein expression was observed in 50% of sporadic CRCs and was significantly more frequent in more advanced cancers. Interestingly, alteration of the fragile FHIT locus and loss of Fhit protein expression were significantly more frequent in sporadic CRCs lacking Msh2 protein, suggesting that this mismatch repair protein may be important in maintaining the integrity of the common fragile locus within the FHIT gene.

This article has been cited by other articles:

				P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF]

				K. Mimori, H. Ishii, H. Nagahara, T. Sudo, K. Yamashita, H. Inoue, G. F. Barnard, and M. Mori FHIT Is Up-Regulated by Inflammatory Stimuli and Inhibits Prostaglandin E2-Mediated Cancer Progression. Cancer Res., March 1, 2006; 66(5): 2683 - 2690. [Abstract] [Full Text] [PDF]

				S. Yendamuri, T. Kuroki, F. Trapasso, A. C. Henry, K. R. Dumon, K. Huebner, N. N. Williams, L. R. Kaiser, and C. M. Croce WW Domain Containing Oxidoreductase Gene Expression Is Altered in Non-Small Cell Lung Cancer Cancer Res., February 15, 2003; 63(4): 878 - 881. [Abstract] [Full Text] [PDF]

				B. C. Turner, M. Ottey, D. B. Zimonjic, M. Potoczek, W. W. Hauck, E. Pequignot, C. L. Keck-Waggoner, C. Sevignani, C. M. Aldaz, P. A. McCue, et al. The Fragile Histidine Triad/Common Chromosome Fragile Site 3B Locus and Repair-deficient Cancers Cancer Res., July 15, 2002; 62(14): 4054 - 4060. [Abstract] [Full Text] [PDF]